
|Articles|January 15, 2004
Generic brimonidine availability yields lower cost to patient
Generic brimonidine tartrate (Bausch & Lomb), which is formulated differently from the trade formulation (Alphagan P, Allergan), became widely available during the second half of 2003 and seems to be gaining acceptance with ophthalmologists in many cases because of the drug's lower cost.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


